Who are we?

ChiraTecnics was founded in 2009 as a spin-out from the University of Évora, with the aim to manufacture and commercialise ligands, building blocks and catalysts for chiral synthesis.

Whilst the company still offers this portfolio to clients, it now mainly focuses on custom synthesis programmes to support medicinal chemistry and drug discovery projects for pharmaceutical and biotech companies. It is led by a strong international team and has access to all vital equipment to implement our projects.


 

News

2018年12月

我们很高兴地宣布,我们是2019年合成与催化国际研讨会(ISySyCat2019)的赞助商,并将参加这一激动人心的活动。

https://isysycat2019.eventos.chemistry.pt/

 


AUDEMARS PIGUET TRADITION REPLICA

2017年5月

第2届国际合成与催化会议(ISySyCat2017)将于2017年9月5日至8日在埃武拉大学举行。希望在那里见到你,我们将:

http://isysycat2017.eventos.chemistry.pt/

 


2015年4月

我们与Évora大学签订了一项合同,将一些新型专利的最先进的手性有机催化剂商业化,这些有机催化剂用于高效的安全工艺(WO2015052656(A1)),以良好的产率和非常好的对映体控制手性胺。 。这些催化剂也可以固定化。 

 


AUDEMARS PIGUET TRADITION REPLICA

 

 

Did you Know?

 

The CRO Market for API and other chemicals is buzzing at the moment.

Revenues in 2010 were $11.43 billion and it is estimated to reach $20.09 billion in 2020. Pharma is outsourcing more and more business to competent CROs.

 

Our mission is to provide

 

 

  • ChiraTecnics is a privately owned CRO with lab installations in the Alentejo Science and Technology Park (PCTA–Evora). We provide contract research services and high-added- value chemicals to the pharmaceutical and other industries. The company is already active in the market. We offer cutting edge chemical technologies, with extensive knowhow and experience, to rapidly respond to our customer’s needs applying the highest standards at the most affordable price. We also have access to an affordable highly qualified work- force. We pride ourselves on our openness, confidentiality and constant communication which is important for our customers and establishing mutual trust. We see our business as a fine art where we work with passion, creativity and flexibility to reliably meet the customers’ needs and expectations.